Abstract
Imatinib is the drug of first choice for most patients with chronic phase chronic myeloid leukemia (CML). Although it is generally well tolerated, a number of hematological and nonhematological side-effects have been described. We report here that imatinib induces hypophosphatemia in a high proportion of our series of CML patients previously treated with interferon alpha, and that this previously unreported side effect is associated with response.
(c) 2006 Wiley-Liss, Inc.
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Benzamides
-
Calcium / blood
-
Cohort Studies
-
Female
-
Humans
-
Hypophosphatemia / chemically induced*
-
Imatinib Mesylate
-
Interferon-alpha / therapeutic use
-
Kidney Tubules / drug effects*
-
Kidney Tubules / metabolism
-
Leukemia, Myeloid, Chronic-Phase / blood
-
Leukemia, Myeloid, Chronic-Phase / drug therapy*
-
Male
-
Middle Aged
-
Parathyroid Hormone / blood
-
Phosphates / metabolism
-
Piperazines / adverse effects
-
Piperazines / pharmacology*
-
Piperazines / therapeutic use
-
Pyrimidines / adverse effects
-
Pyrimidines / pharmacology*
-
Pyrimidines / therapeutic use
-
Retrospective Studies
-
Treatment Outcome
Substances
-
Benzamides
-
Interferon-alpha
-
Parathyroid Hormone
-
Phosphates
-
Piperazines
-
Pyrimidines
-
Imatinib Mesylate
-
Calcium